Abstract 438P
Background
Immune checkpoint inhibitors (ICIs) demonstrate efficacy against various cancers by activating the immune response against neoplasia. On the other hand, ICI-related myocarditis, which has a high mortality rate, is known to occur as adverse event. Therefore, safe ICI therapy should be established worldwide. In the present study, we developed a mouse model of ICI-related myocarditis and evaluated the efficacy of vitamin D, which exerts therapeutic effects on autoimmune myocarditis.
Methods
PD-1 knockout (PD-1KO) mice were treated with the myocardial myosin peptide and pertussis toxin to create a mouse model of ICI-related myocarditis. After 21 days of myocardial myosin peptide administration, their hearts were dissected and evaluated for the development of myocarditis. In addition, vitamin D, a candidate drug, was administered to the model mice every other day to evaluate its effect on the severity of myocarditis.
Results
Administering the myocardial myosin peptide to PD-1KO mice resulted in infiltration of inflammatory cells into the myocardial tissue and progressive myocardial fibrosis. Fluorescent immunostaining showed infiltration of CD4⁺ and CD8⁺ T cells in the myocardial tissue. Inflammatory cell infiltration was significantly suppressed in the vitamin D-treated group than in the vehicle group, as was CD4⁺ and CD8⁺ T cell infiltration. There was a trend toward suppression of myocardial fibrosis with vitamin D administration, although without statistical significance.
Conclusions
By administering the myocardial myosin peptide to PD-1KO mice, we generated a simple and reproducible experimental model of ICI-related myocarditis. Furthermore, vitamin D attenuated the infiltration of inflammatory cells and prevented the onset of ICI-related myocarditis in the model mice. The application of vitamin D as a prophylactic agent for ICI-related myocarditis should be investigated in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Japan Society for the Promotion of Science.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract